Trial Profile
Dose induction PEG-Intron [peginterferon alfa-2b] in combination with Rebetol [ribavirin] enhance the sustained response rates in patients with chronic hepatitis C.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Peginterferon alfa-2b (Primary) ; Ribavirin
- Indications Hepatitis C
- Focus Therapeutic Use
- 13 Feb 2012 Actual patient number changed from 604 to 610 as reported by ClinicalTrials.gov.
- 13 Feb 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 25 Oct 2008 Primary endpoint 'sustained virological response rate' has not been met in 604 patients analysed 24 weeks after end-of-treatment.